Ketamine infusions for depression are spreading to more clinics because the treatment fills a critical gap that traditional antidepressants cannot — rapid relief for patients who have exhausted other options, often within hours rather than weeks. With the FDA’s 2019 approval of esketamine (Spravato) for treatment-resistant depression and a growing body of research supporting off-label intravenous ketamine, hundreds of private clinics have opened across the United States in the past five years. A patient in Austin, Texas, who spent twelve years cycling through SSRIs, SNRIs, and tricyclics without adequate relief might now find three ketamine clinics within a twenty-minute drive, a situation that would have been unthinkable a decade ago.
This expansion matters for brain health broadly, and for families dealing with dementia in particular. Depression is both a risk factor for cognitive decline and a common companion to early-stage dementia diagnoses, affecting up to 40 percent of people with Alzheimer’s disease. When conventional treatments fail or carry side effects that worsen confusion in older adults, ketamine therapy represents a genuinely different pharmacological approach. This article examines why clinics are multiplying so quickly, what the science actually supports, the real limitations and risks involved, how ketamine relates to brain health beyond mood, and what families should weigh before pursuing this option for themselves or a loved one.
Table of Contents
- Why Are Ketamine Clinics for Depression Growing So Rapidly?
- What Does the Research Actually Show About Ketamine and Depression?
- How Ketamine’s Effects on the Brain Connect to Cognitive Health
- What Should Families Consider Before Pursuing Ketamine Treatment?
- Risks, Side Effects, and the Question of Long-Term Safety
- How to Evaluate a Ketamine Clinic’s Quality
- Where Ketamine Research Is Heading
- Conclusion
- Frequently Asked Questions
Why Are Ketamine Clinics for Depression Growing So Rapidly?
The primary driver is unmet need. Roughly 30 percent of people with major depressive disorder do not respond adequately to two or more standard antidepressant trials, placing them in the treatment-resistant category. That represents millions of Americans stuck in a therapeutic dead end. Ketamine works through a fundamentally different mechanism — modulating glutamate and NMDA receptors rather than serotonin or norepinephrine — which means it can help patients whose brain chemistry simply does not respond to the usual targets. The speed of onset is equally compelling. Where SSRIs typically require four to six weeks to reach full effect, a single ketamine infusion can reduce suicidal ideation within hours, according to research published in the American Journal of Psychiatry. The business model has also made expansion straightforward. Unlike complex surgical centers or imaging facilities, a ketamine clinic requires relatively modest infrastructure: a medical director, trained nursing staff, monitoring equipment, a comfortable infusion room, and the drug itself, which is inexpensive and widely available as a generic.
Startup costs are low by medical standards, and because most ketamine infusions are paid out of pocket — typically between $400 and $800 per session — clinics avoid the bureaucratic friction of insurance negotiations. This cash-pay structure has attracted both psychiatrists genuinely motivated by patient need and, frankly, entrepreneurs who see a profitable niche. The result is rapid, uneven growth. In metropolitan areas, patients may have multiple clinics competing for their business. In rural communities, access remains sparse. A useful comparison is the early expansion of urgent care centers in the 2000s. Those clinics also grew quickly because they addressed a gap — convenient, immediate care — that the existing system was too slow to provide. Ketamine clinics are following a similar trajectory, though the stakes of quality variation are arguably higher when the treatment involves an anesthetic agent and a vulnerable psychiatric population.
What Does the Research Actually Show About Ketamine and Depression?
The evidence base for ketamine in depression is real but comes with important caveats. Multiple randomized controlled trials have demonstrated that a single intravenous ketamine infusion at sub-anesthetic doses (typically 0.5 mg/kg over 40 minutes) produces rapid antidepressant effects in 50 to 70 percent of treatment-resistant patients. A landmark 2006 study by Zarate and colleagues at the National Institute of Mental Health showed significant improvement within two hours of infusion, a finding that has been replicated numerous times. The FDA-approved nasal spray esketamine (Spravato) went through Phase III trials involving over 1,700 patients and showed statistically significant improvement when combined with an oral antidepressant. However, the duration of benefit is the treatment’s most significant limitation. The antidepressant effects of a single infusion typically fade within one to two weeks. this means ketamine is not a one-and-done cure; it requires repeated sessions, usually a series of six infusions over two to three weeks as an initial course, followed by maintenance infusions that might range from monthly to every few months.
Long-term data beyond a year or two is still limited. If a patient responds well initially but cannot afford or access ongoing maintenance, the depression is likely to return. Researchers at Massachusetts General Hospital and Yale have been working on understanding why some patients maintain improvement longer than others, but no reliable predictor has emerged yet. The distinction between IV ketamine and the nasal spray matters too. Esketamine (Spravato) is the S-enantiomer of ketamine, must be administered in a certified healthcare setting under a Risk Evaluation and Mitigation Strategy (REMS) program, and is covered by some insurance plans. Generic IV ketamine is used off-label, is not FDA-approved for depression specifically, and is almost never covered by insurance. Both appear to work, but they are not interchangeable in terms of regulation, cost structure, or monitoring requirements.
How Ketamine’s Effects on the Brain Connect to Cognitive Health
Beyond its antidepressant properties, ketamine has drawn interest from neuroscientists studying neuroplasticity — the brain’s ability to form new synaptic connections. Research in animal models, particularly work led by Ronald Duman at Yale before his passing in 2020, showed that ketamine rapidly increases the expression of brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis in the prefrontal cortex. In plain terms, ketamine appears to help damaged or weakened neural connections rebuild, at least temporarily. This is relevant to dementia research because synaptic loss is one of the earliest and most consistent features of Alzheimer’s disease. A specific example illustrates the connection. A 2019 study published in Translational Psychiatry examined older adults with treatment-resistant depression and mild cognitive impairment.
After a course of ketamine infusions, participants showed not only mood improvement but also modest gains on certain cognitive tests measuring processing speed and executive function. The researchers cautioned that these cognitive benefits were likely secondary to mood improvement rather than direct neuroprotective effects, and the sample size was small. Still, the finding raised legitimate questions about whether ketamine’s synaptic repair mechanisms might have applications beyond depression. Families dealing with a loved one who has both depression and early cognitive decline should understand that ketamine is not being studied or marketed as a dementia treatment. The neuroplasticity research is promising at a mechanistic level, but no clinical trial has demonstrated that ketamine slows or reverses Alzheimer’s pathology. What it may do is treat the depression that worsens cognitive function, quality of life, and caregiver burden — and that alone can be meaningful.
What Should Families Consider Before Pursuing Ketamine Treatment?
The first practical consideration is medical screening. Ketamine raises blood pressure and heart rate during infusion, which means patients with uncontrolled hypertension, a history of aneurysm, or certain cardiac conditions may not be candidates. For older adults, who are more likely to have cardiovascular concerns, this screening is especially important. A reputable clinic will require recent bloodwork, a cardiac history review, and sometimes clearance from a primary care physician or cardiologist before proceeding. Any clinic that skips this step or conducts only a cursory intake should be avoided. The tradeoff between IV ketamine and Spravato is worth weighing carefully. Spravato has the advantage of insurance coverage for eligible patients, which can reduce out-of-pocket costs significantly, though prior authorization requirements and the need for a REMS-certified provider can limit access. IV ketamine offers more dosing flexibility — the prescribing physician can adjust the dose, infusion rate, and frequency based on individual response — but the full cost falls on the patient.
A typical initial course of six IV infusions might cost $2,400 to $4,800, with maintenance sessions adding ongoing expense. For families already managing the financial burden of dementia care, this is not a trivial consideration. The second tradeoff involves the treatment setting itself. Spravato must be administered in a certified clinic where the patient is monitored for at least two hours, which provides a safety net but also requires time and transportation. IV ketamine clinics vary widely in their monitoring protocols and follow-up care. Some integrate the infusions with ongoing psychotherapy, which research suggests improves outcomes. Others operate more like infusion mills, providing the drug without meaningful psychiatric support. Asking about the clinic’s approach to therapy integration, their protocol if a patient has a difficult dissociative experience, and their plan for long-term management is essential before committing.
Risks, Side Effects, and the Question of Long-Term Safety
The most common immediate side effects of ketamine infusion are dissociation, nausea, dizziness, and elevated blood pressure. Dissociation — a feeling of detachment from one’s body or surroundings — is inherent to the drug’s mechanism and occurs in most patients to some degree. For people with a history of psychosis or certain dissociative disorders, this effect can be destabilizing, which is why these conditions are generally considered contraindications. Most side effects resolve within one to two hours after the infusion ends, and serious adverse events during monitored clinical infusions are rare. The longer-term safety question is less settled. Chronic ketamine abuse is associated with bladder damage (interstitial cystitis), liver toxicity, and cognitive impairment.
These effects have been documented primarily in recreational users consuming far higher and more frequent doses than clinical protocols, but they raise legitimate concerns about what happens with years of maintenance infusions. A patient receiving one infusion per month is not pharmacologically equivalent to someone using ketamine recreationally several times a week, but the honest answer is that we do not yet have robust long-term safety data for clinical use spanning five or ten years. The American Psychiatric Association has acknowledged this gap and recommended ongoing monitoring of patients receiving repeated ketamine treatments. A particular warning applies to older adults with cognitive concerns. Ketamine’s dissociative and cognitive effects during and shortly after infusion can mimic or temporarily worsen confusion, which may be especially distressing for someone already experiencing memory problems or for their family members observing the session. Clinicians experienced with geriatric patients will start with lower doses and titrate carefully, but families should ask specifically about the provider’s experience treating older adults and their protocol for managing acute confusion.
How to Evaluate a Ketamine Clinic’s Quality
Not all ketamine clinics operate at the same standard, and the rapid expansion of the field has outpaced regulatory oversight in some areas. A practical example: in 2022, the FDA issued a warning about compounded ketamine products being marketed directly to consumers, some through telehealth platforms offering at-home use with minimal medical supervision. At least one patient death was linked to unsupervised at-home ketamine use.
This is a fundamentally different risk profile from monitored clinical infusions. When evaluating a clinic, look for board-certified physicians (psychiatrists or anesthesiologists) overseeing treatment, clear protocols for vital sign monitoring during every session, a comprehensive psychiatric intake that reviews diagnosis and treatment history, integration with the patient’s existing mental health providers, transparent pricing, and a willingness to discuss what happens if the treatment does not work. A clinic that guarantees results or pressures patients into expensive upfront packages should raise concerns.
Where Ketamine Research Is Heading
The next phase of ketamine-related research is focused on two goals: making the benefits last longer and understanding who responds best. Several pharmaceutical companies are developing next-generation glutamate-modulating drugs that aim to replicate ketamine’s rapid antidepressant effect without the dissociative side effects or the need for clinical monitoring. One such compound, developed under the working name PCN-101 (arketamine), has shown promise in early trials in Japan and is now in Phase III studies. If successful, these drugs could shift treatment from infusion clinics to oral medications taken at home.
For the dementia and brain health community specifically, the neuroplasticity research remains the most intriguing thread. The National Institute on Aging has funded several small studies examining whether ketamine-induced BDNF release has measurable effects on biomarkers of neurodegeneration. Results are expected over the next two to three years. Even if ketamine itself does not become a cognitive therapy, the glutamate signaling pathways it has illuminated are now considered legitimate targets for Alzheimer’s drug development — a contribution that may ultimately matter more than the infusion clinics themselves.
Conclusion
Ketamine infusions have spread to more clinics because they offer something the existing antidepressant arsenal cannot: rapid relief for patients who have run out of conventional options. The science behind the treatment is legitimate, grounded in a distinct pharmacological mechanism, and supported by controlled trials. But the expansion has also been driven by a cash-pay business model that operates largely outside insurance systems and, in some cases, outside rigorous quality standards. For families navigating both depression and cognitive decline, the treatment represents a real but bounded option — one that may help with mood even as its effects on dementia pathology remain unproven.
The practical path forward is informed selectivity. Choose a clinic with qualified medical oversight, realistic expectations about duration of benefit, integration with ongoing psychiatric care, and experience with older adults if that is the relevant population. Discuss the financial commitment openly, understand that maintenance treatment is likely necessary, and keep communicating with the broader care team. Depression in the context of brain aging is not a problem to accept passively, and ketamine is one more tool — imperfect, still evolving, but genuinely useful for the right patient in the right setting.
Frequently Asked Questions
Is ketamine FDA-approved for depression?
Esketamine (Spravato), a nasal spray form, is FDA-approved for treatment-resistant depression and must be administered in a certified clinic. Standard IV ketamine is used off-label for depression and is not FDA-approved for that purpose, though it is a legal, FDA-approved drug for anesthesia.
How quickly does ketamine work for depression?
Many patients notice improvement within hours to days of a first infusion, which is dramatically faster than traditional antidepressants. However, the effect of a single infusion typically lasts one to two weeks, requiring repeated sessions for sustained benefit.
Does insurance cover ketamine infusions?
Most insurance plans do not cover off-label IV ketamine infusions. Spravato (esketamine nasal spray) is covered by some plans, often after documentation that other treatments have failed. Patients should verify coverage before beginning treatment.
Is ketamine safe for older adults?
Ketamine can be used in older adults, but cardiovascular screening is essential since the drug raises blood pressure and heart rate. Lower starting doses and experienced clinicians are important. People with uncontrolled hypertension or significant cardiac disease may not be candidates.
Can ketamine help with dementia?
Ketamine is not approved or proven as a treatment for dementia. Research on its neuroplasticity effects is ongoing but preliminary. It may help treat depression that co-occurs with dementia, which can indirectly improve cognitive function and quality of life.
What are the risks of long-term ketamine use?
Chronic recreational use is linked to bladder damage, liver problems, and cognitive impairment. Clinical doses are much lower, but long-term safety data beyond one to two years of maintenance treatment is limited. Ongoing medical monitoring is recommended for anyone receiving repeated infusions.
